What are the recent newly listed stocks (10.14)
Do you know what are the newly listed stocks, or where to check the newly listed stocks, there are a lot of stocks applying for subscription recently. So today I'm here to organize the recent newly listed stocks, let's take a look together!
Xinling Electric 301388
April 26, Xinling Electric Co., Ltd. (hereinafter referred to as: Xinling Electric) in the Shenzhen Stock Exchange GEM on the meeting through, and May 27 submitted for registration, by Guotai Junan Securities as the sponsor.
Publicly available information shows that Xinling Electric public offering of no more than 25,611,900 shares, accounting for 25% of the total share capital of the company after the issue. Expected to raise funds of 413 million yuan, of which 291 million yuan for industrial automation control electrical components intelligent manufacturing plant construction project, 0.65 billion yuan for electromagnetic relay, micro switch production line construction project and 0.057 billion yuan for intelligent power distribution electrical production line construction project.
However, it is worth noting that more than half of the research and development personnel of Xinling Electric education for college and below, its research and development level has been questioned. In addition, Xinling Electric distribution customers are mostly former employees, the transaction is doubtful. In response to the above issues, found that the network to the Xinling Electric public mailbox to send an interview letter requesting interpretation, however, as of press time, Xinling Electric did not give a reasonable explanation.
Huaxia Ophthalmology 301267
Huaxia Ophthalmology (301267.SZ) disclosed the prospectus, the company intends to make an initial public offering of 60 million shares, accounting for the proportion of post-offering share capital of 10.71%, the total share capital of the post-offering share capital of 560 million shares. The initial inquiry date is Oct. 19, 2022, and the subscription date is Oct. 24, 2022, the company said.
The announcement shows that the company is a large private medical chain group focusing on ophthalmic specialty medical services, as of the date of the prospectus, the company has opened 57 ophthalmic specialty hospitals in China, covering 17 provinces and 46 cities, radiating a wide range of regions in China, such as East China, Central China, South China, Southwest China and North China, etc. In 2021, the company's annual outpatient visits amounted to 1,671,400 visits In 2021, the company's annual outpatient visits will reach 1,671,400, and the number of operated eyes for ophthalmic surgery will reach 292,800, realizing a revenue of 3.007 billion yuan from its main business.
It is reported that the company's net profit attributable to owners of the parent company will be $218 million, $334 million and $455 million in 2019, 2020 and 2021, respectively. In addition, the company is expected to realize operating revenues of $2.52 billion to $2.54 billion from January to September 2022, representing a year-on-year growth of 10.02% to 10.89%. Net profit attributable to shareholders of the parent company will range from $395 million to $405 million, up 17.34% to 20.31% year-on-year. Net profit attributable to shareholders of the parent company after extraordinary gains and losses of 425 million to 435 million yuan, up 18.39 percent to 21.18 percent.
Yunzhongma 603130
Zhejiang Yunzhongma Co., Ltd. specializes in the research, development, production and sales of leather base fabric, the base material of synthetic leather. The main products are knitted leather base cloth. The main honors won by the company in recent years include the city's top 100 taxpaying enterprises in manufacturing industry, the 2020 National Business Quality Award, the provincial-level high-tech enterprise research and development center, the top 10 enterprises of leather base cloth in China's artificial leather synthetic leather industry, and the provincial-level cultivation enterprise of manufacturing single champion.
JHJY 301367
Beijing JHJY Medical Technology Co., Ltd. is a leading manufacturer of medical equipments and consumables in the field of respiratory health in China, and its main products include non-invasive home ventilators, ventilation masks, sleep monitors, and high-flow humidification oxygen therapy devices, and it also provides respiratory health chronic disease management services.
The company integrates independent research and development, production, sales and related services, and adheres to the tenet of "care for the home", focusing on providing services for patients with obstructive sleep apnea hypopnea (OSA)-based sleep apnea hypopnea syndrome (SAHS), and chronic obstructive pulmonary disease (COPD), as well as respiratory insufficiency (COPD), and other chronic diseases. RespiratoryInsufficiency (RI) patients with predominantly OSA, and Chronic Obstructive Pulmonary Disease (COPD), providing the full cycle (from diagnosis, to treatment, to chronic disease management).